tirzepatide surmount 1 after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial SURMOUNT-1: Tirzepatide Drastically Reduces Weight
Description
Yin Y, Li Y, Shao L, Yuan S, Liu B, Lin S, et al
The medication is administered once weekly via subcutaneous injection, with doses gradually titrated to minimise gastrointestinal side effects
Our approach to analytical verification is described on the Quality Testing page, which outlines the methods used to assess identity and purity
Variants in the GLP1R gene, such as rs6923761, influence how effectively your cells respond to the medication and may affect the optimal dose for your body
Patients should consume sufficient water throughout the day
If your plan requires it, we develop a plan to either satisfy the requirement efficiently or request an exception with supporting documentation
